Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 3
2011 11
2012 11
2013 11
2014 30
2015 26
2016 28
2017 32
2018 27
2019 25
2020 24
2021 18
2022 20
2023 17
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

275 results

Results by year

Filters applied: . Clear all
Page 1
Platinum-ineligible: atezolizumab preferable.
Killock D. Killock D. Nat Rev Clin Oncol. 2023 Oct;20(10):661. doi: 10.1038/s41571-023-00806-6. Nat Rev Clin Oncol. 2023. PMID: 37479811 No abstract available.
Moving pembrolizumab forwards.
Killock D. Killock D. Nat Rev Clin Oncol. 2020 Apr;17(4):196. doi: 10.1038/s41571-020-0349-3. Nat Rev Clin Oncol. 2020. PMID: 32127649 No abstract available.
Newly diagnosed AML: quizartinib improves OS.
Killock D. Killock D. Nat Rev Clin Oncol. 2023 Aug;20(8):504. doi: 10.1038/s41571-023-00787-6. Nat Rev Clin Oncol. 2023. PMID: 37253972 No abstract available.
Ivosidenib combination improves OS.
Killock D. Killock D. Nat Rev Clin Oncol. 2022 Jul;19(7):427. doi: 10.1038/s41571-022-00644-y. Nat Rev Clin Oncol. 2022. PMID: 35534622 No abstract available.
Abemaciclib crowned in monarchE.
Killock D. Killock D. Nat Rev Clin Oncol. 2022 Jan;19(1):5. doi: 10.1038/s41571-021-00578-x. Nat Rev Clin Oncol. 2022. PMID: 34716415 No abstract available.
Beware trial end point comparisons.
Killock D, Hutchinson L. Killock D, et al. Nat Rev Clin Oncol. 2016 Aug 19;13(9):525. doi: 10.1038/nrclinonc.2016.132. Nat Rev Clin Oncol. 2016. PMID: 27538975 No abstract available.
Tebentafusp for uveal melanoma.
Killock D. Killock D. Nat Rev Clin Oncol. 2021 Dec;18(12):747. doi: 10.1038/s41571-021-00572-3. Nat Rev Clin Oncol. 2021. PMID: 34625736 No abstract available.
Camrelizumab efficacious in NPC.
Killock D. Killock D. Nat Rev Clin Oncol. 2021 Sep;18(9):542. doi: 10.1038/s41571-021-00542-9. Nat Rev Clin Oncol. 2021. PMID: 34253913 No abstract available.
Engaging results with glofitamab.
Killock D. Killock D. Nat Rev Clin Oncol. 2021 May;18(5):257. doi: 10.1038/s41571-021-00510-3. Nat Rev Clin Oncol. 2021. PMID: 33828233 No abstract available.
Long-term data on tisagenlecleucel.
Killock D. Killock D. Nat Rev Clin Oncol. 2021 Nov;18(11):676. doi: 10.1038/s41571-021-00567-0. Nat Rev Clin Oncol. 2021. PMID: 34580475 No abstract available.
275 results